Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs.

International journal of nanomedicine

Volumn 6, Issue , 2011, Pages 2205-2212

  Axiak, Sandra M ^a   Selting, Kim A ^b   Decedue, Charles J ^b   Henry, Carolyn J ^b   Tate, Deborah ^b   Howell, Jahna ^b   Bilof, K James ^b   Kim, Dae Y ^b  

^a UNIVERSITY OF MISSOURI   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NANOPARTICLE; PACLITAXEL;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CHEMISTRY; DOG; DOG DISEASE; DRUG DELIVERY SYSTEM; KIDNEY; LIVER; METABOLISM; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHASE 1 CLINICAL TRIAL (TOPIC); SPLEEN; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS, PHASE I AS TOPIC; DOG DISEASES; DOGS; DRUG DELIVERY SYSTEMS; KIDNEY; LIVER; NANOPARTICLES; NEOPLASMS; PACLITAXEL; SPLEEN; TISSUE DISTRIBUTION;

MLCS; MLOWN;

EID: 84873039087     PISSN: None     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/ijn.s24823     Document Type: Article

References (0)